Psychiatric Genomics Consortium Bipolar Datasets
The Psychiatric Genomics Consortium (PGC) sent their full sample bipolar GWAS results, individual quality controlled genotypes, and individual level dosage data (from an imputation model) for a subset of the full sample (i.e., "deposited data") to the NIMH Repository for distribution to qualified investigators. The PGC was founded in 2007 to conduct meta-analyses of genome wide data on psychiatric disorders. A major goal of the PGC is sharing data with the international scientific community. More information on the PGC may be found at their website (https://www.med.unc.edu/pgc).
PGC Bipolar Datasets
The PGC sent summary statistics for the full BP sample, n=16731. In addition, subject-level data (original and imputed dosage genotypes) is provided for a subset of n=7,272 individuals, which excludes four samples (studies) due to restrictions on data sharing (see Table). The dosage genotype data is the result of an imputation model where fully observed snps are coded 0, 1, 2 and imputed snps have a single dosage on the interval [0,2]. The studies in the PGC that also have blood samples and/or phenotype data in the NIMH Repository are the GAIN and STEP-BD studies for BP cases, and the Gejman MGS controls for BP controls. Files available for download by authorized users include plots (Manhattan and QQ), a list of the top 1,000 SNPs, PLINK files of genotype data for individual datasets, and imputed dosage data for 2.4 M SNPs.
| Sample | Ancestry | Cases | Controls | Platform |
|---|---|---|---|---|
| BOMA-Bipolar Study, University of Bonn and CIMH Mannheim | German | 675 | 1,297 | Not distributed through NIMH |
| Genetic Association Information Network (GAIN) / Bipolar Genome Study (BiGS) | European-American | 542 | 649 | Not distributed through NIMH |
| GlaxoSmithKline (GSK) | British, Canadian or Scottish | 890 | 902 | Not publicly available |
| Pritzker Neuropsychiatric Disorders Research Consortium | European-American | 1,130 | 718 | Illumina 550K |
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP1) | European-American | 922 | 645 | Affymetrix 500K |
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP2) | European-American | 659 | 192 | Affymetrix 5.0 |
| Thematically Organized Psychosis (TOP) Study | Norwegian | 203 | 349 | Affymetrix 6.0 |
| Trinity College Dublin | Irish | 150 | 797 | Affymetrix 6.0 |
| University College London (UCL) | British | 457 | 495 | Affymetrix 500K |
| University of Edinburgh | Scottish | 282 | 275 | Affymetrix 6.0 |
| Wellcome Trust Case-Control Consortium (WTCCC) | British | 1,571 | 2,931 | Available through WTCCC |